Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 13/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 13/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | HTR2B | P41595 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | THPO | P40225 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1539259 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29424270 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9671595 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7056295 | 0.89 | MTNR1A (0.80) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7056004 | 0.89 | MTNR1A (0.80) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7051405 | 0.88 | MTNR1A (0.78) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4967386 | 0.86 | MTNR1A (0.76) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13390756 | 0.86 | MTNR1A (0.76) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL18222529 | 0.86 | MTNR1A (0.76) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4963214 | 0.86 | MTNR1A (0.76) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3217973-A1 | MELATONIN IN AUTOIMMUNE DISEASE | The Brigham and Women's Hospital, Inc. (US) | 2017-09-20 | — | — | EP | claimed |
| WO-2016077654-A1 | MELATONIN IN AUTOIMMUNE DISEASE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-05-19 | — | — | WO | claimed |
| EP-2275096-A2 | Neurogenesis via modulation of the muscarinic receptors | Braincells, Inc. (US) | 2011-01-19 | — | — | EP | claimed |
| EP-2275095-A2 | Neurogenesis by muscarinic receptor modulation | Braincells, Inc. (US) | 2011-01-19 | — | — | EP | claimed |
| EP-2258359-A2 | Neurogenesis by muscarinic receptor modulation with sabcomelin | Braincells, Inc. (US) | 2010-12-08 | — | — | EP | claimed |
| EP-2258357-A2 | Neurogenesis with acetylcholinesterase inhibitor | Braincells, Inc. (US) | 2010-12-08 | — | — | EP | claimed |
| EP-1898906-A2 | METHODS OF TREATMENT UTILIZING CERTAIN MELATONIN DERIVATIVES | Phase 2 Discovery (US) | 2008-03-19 | — | — | EP | claimed |
| WO-2006105455-A2 | METHODS OF TREATMENT UTILIZING CERTAIN MELATONIN DERIVATIVES | PHASE 2 DISCOVERY (US) | 2006-10-05 | — | — | WO | claimed |
| US-20060223877-A1 | Methods of treatment utilizing certain melatonin derivatives | PHASE 2 DISCOVERY, INC. | 2006-10-05 | — | — | US | claimed |
| US-12201604-B2 | Treatment of circadian rhythm disorders | VANDA PHARMACEUTICALS INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240156775-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | VANDA PHARMACEUTICALS INC. | 2024-05-16 | — | — | US | disclosed |
| US-11918557-B2 | Treatment of circadian rhythm disorders | VANDA PHARMACEUTICALS INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-11845990-B2 | Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype | VANDA PHARMACEUTICALS INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230210810-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | VANDA PHARMACEUTICALS INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2006105455-A2 | METHODS OF TREATMENT UTILIZING CERTAIN MELATONIN DERIVATIVES | PHASE 2 DISCOVERY (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006105455-A2 | METHODS OF TREATMENT UTILIZING CERTAIN MELATONIN DERIVATIVES | PHASE 2 DISCOVERY (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060223877-A1 | Methods of treatment utilizing certain melatonin derivatives | PHASE 2 DISCOVERY, INC. | 2006-10-05 | — | — | US | disclosed |
| EP-0281242-B1 | BETA-ALKYLMELATONINS | ELI LILLY AND COMPANY (US) | 1992-08-12 | — | — | EP | disclosed |
| US-4997845-A | β-alkylmelatonins as ovulation inhibitors | ELI LILLY AND COMPANY (US) | 1991-03-05 | — | — | US | disclosed |
| EP-0281242-A1 | Beta-alkylmelatonins | ELI LILLY AND COMPANY (US) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12201604-B2 | Treatment of circadian rhythm disorders | CRY1, PER2, CRY2 | MTNR1A 4/4885MTNR1B 5/4885CYP1A2 256/4885 |
| US-20240156775-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | CRY1, PER2, CRY2 | MTNR1A 4/4885MTNR1B 5/4885CYP1A2 256/4885 |
| US-20230210810-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | CRY1, PER2, CRY2 | MTNR1A 4/4885MTNR1B 5/4885CYP1A2 256/4885 |
| US-20060223877-A1 | Methods of treatment utilizing certain melatonin derivatives | MTNR1A, MTNR1B, HTR6 | MTNR1A 1/4885MTNR1B 2/4885CYP1A2 1226/4885 |
| US-11845990-B2 | Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype | PER2, CRY1, NR1I3 | MTNR1A 13/4885MTNR1B 37/4885CYP1A2 171/4885 |
| US-11918557-B2 | Treatment of circadian rhythm disorders | CRY1, PER2, CRY2 | MTNR1A 4/4885MTNR1B 5/4885CYP1A2 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.